argenex SE $ARGX is Eagle Health Investments LP’s Largest Position

Eagle Health Investments LP lowered its position in shares of argenex SE (NASDAQ:ARGX) by 19.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 62,730 shares of the company’s stock after selling 14,700 shares during the quarter. argenex comprises approximately 11.6% of Eagle Health Investments LP’s holdings, making the stock its largest holding. Eagle Health Investments LP owned approximately 0.10% of argenex worth $52,753,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of argenex by 91.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock worth $6,511,000 after purchasing an additional 4,217 shares during the period. American Century Companies Inc. boosted its holdings in argenex by 11.6% in the 3rd quarter. American Century Companies Inc. now owns 229,770 shares of the company’s stock worth $169,474,000 after acquiring an additional 23,864 shares during the period. Allianz Asset Management GmbH boosted its holdings in argenex by 21.3% in the 3rd quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock worth $2,708,000 after acquiring an additional 645 shares during the period. US Bancorp DE boosted its holdings in argenex by 37.2% in the 3rd quarter. US Bancorp DE now owns 7,073 shares of the company’s stock worth $5,217,000 after acquiring an additional 1,919 shares during the period. Finally, Alta Wealth Advisors LLC purchased a new position in argenex in the 3rd quarter worth approximately $623,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. HC Wainwright upped their price target on argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Deutsche Bank Aktiengesellschaft upgraded argenex from a “hold” rating to a “buy” rating in a report on Tuesday, March 10th. Glj Research raised argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Finally, Guggenheim upped their target price on argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, argenex has a consensus rating of “Moderate Buy” and an average price target of $1,017.78.

argenex Stock Up 0.8%

Shares of ARGX opened at $804.25 on Thursday. The business’s 50 day moving average is $764.13 and its two-hundred day moving average is $815.95. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62. The firm has a market cap of $49.77 billion, a price-to-earnings ratio of 35.81, a PEG ratio of 1.26 and a beta of 0.46.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%.The firm had revenue of $1.31 billion for the quarter. On average, equities analysts expect that argenex SE will post 25.27 earnings per share for the current fiscal year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.